Delpharm production activities resume and Sandoz confirms over 90% availability of its injectables

Once again, Sandoz Canada shows the strength of its supply chain by confirming that over 90% of its Delpharm products are available, even after a four-week strike at the plant. As soon as production activities resumed, essential medicines and those with lower stock levels were prioritized.

At Sandoz, we take the necessary steps to meet our patients’ needs every day. In the case of the Delpharm strike, several key elements worked in our favour: the plant’s proximity, our collaborative partnership with Delpharm and our hospital distributor McKesson, our strong relationships with GPOs, customers, partners and hospitals, and our inventory and supply management expertise.

Thanks to all these factors, we’re able to minimize the number of supply shortages. We currently have under 10 back-ordered products out of the 115 injectables that are produced at the Delpharm plant. We’ll also increase safety stocks at year-end to return to the high levels we need to meet the growing demand for our products, especially since post-Covid surgeries resumed across the country.

As usual, we’ll continue to post the availability of our injectable products weekly on our website and share it with hospital and community pharmacists. We also remain in close contact with Health Canada, our customers and distributors, and hospital GPOs to continue to ensure adequate supply in all circumstances.

We celebrate the successful renewal of the collective agreement between Delpharm and the Teamsters local union and are thrilled that the situation has been resolved for the plant’s employees.

Our entire team believes deeply in keeping patients at the core of our decisions, which has made us a leader in Canada for generic injectables in hospital and community settings.

Michel Robidoux
President and General Manager
Sandoz Canada